Publications
Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 71-88.
"The Development of TALE Nucleases for Biotechnology." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 27-42.
"Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochem Biophys Res Commun 478, no. 3 (2016): 1484-1490.
"Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature methods 13, no. 2 (2016): 127-137.
"Engineering Delivery Vehicles for Genome Editing." Annual review of chemical and biomolecular engineering 7 (2016): 637-662.
"Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy." Human genetics 135, no. 9 (2016): 1029-1040.
"Genome-editing Technologies for Gene and Cell Therapy." Molecular therapy : the journal of the American Society of Gene Therapy 24, no. 3 (2016): 430-446.
"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." Science 351, no. 6271 (2016): 403-407.
"In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA." Mol Ther 24, no. 4 (2016): 697-706.
"N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions." Scientific reports 6 (2016).
"Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells." Cell Stem Cell 19, no. 3 (2016): 406-414.
"Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic acids research 45, no. 20 (2017).
"CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues." Arthritis & rheumatology (Hoboken, N.J.) 69, no. 5 (2017): 1111-1121.
"CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nat Biotechnol 35, no. 6 (2017): 561-568.
"Editorial Overview: Synthetic biology and biomedical engineering." Current Opinion in Biomedical Engineering 4 (2017): vi - vii.
"An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis." ACS synthetic biology 6, no. 11 (2017): 2003-2013.
"Expanding the CRISPR Toolbox: Targeting RNA with Cas13b." Molecular cell 65, no. 4 (2017): 582-584.
"Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nat Commun 8 (2017).
"Genetic engineering: Chemical control for CRISPR editing." Nature chemical biology 13, no. 1 (2017): 2-3.
"Genome engineering: a new approach to gene therapy for neuromuscular disorders." Nature reviews. Neurology 13, no. 11 (2017): 647-661.
"Genome Engineering for Personalized Arthritis Therapeutics." Trends in molecular medicine 23, no. 10 (2017): 917-931.
"Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs." Stem cell reports 8, no. 5 (2017): 1202-1213.
"Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies." Nucleic Acids Res 45, no. 20 (2017): 11684-11699.
"Loss-of-function genetic tools for animal models: cross-species and cross-platform differences." Nature reviews. Genetics 18, no. 1 (2017): 24-40.
"Mammalian Synthetic Biology: Engineering Biological Systems." Annual review of biomedical engineering 19 (2017): 249-277.
"